• PepGen launched a proposed $125 million public offering of common stock, with pre-funded warrants available to certain investors instead of shares.
• Underwriters will receive a 30-day option to purchase up to $18.75 million of additional common stock.
• Net proceeds will fund ongoing clinical development of its product candidate, working capital and other general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261110685728) on November 10, 2026, and is solely responsible for the information contained therein.